Close Menu

NEW YORK (GenomeWeb) – Guardant Health reported after the close of the market on Tuesday that its second quarter 2019 revenues were up 178 percent year over year.

The liquid biopsy firm reported total revenues of $54.0 million for the quarter ended June 30, compared to $19.4 million in the same period of 2018, handily beating the $36.4 million that Wall Street had predicted on average.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.